Stock Mumak
Inside Umbrella | Stocks

Stock Profile

AbbVie

AbbVie is one of the leading pharmaceutical companies worldwide. Skyrizi and Rinvoq are driving growth, while patent expirations and competitive pressure remain key risks.

Stock Snapshot

AbbVie_logo
Table HeaderTable Header
CompanyAbbVie Inc.
SectorHealthcare
ThemeImmunology, Oncology & Neuroscience
Business ModelDevelopment and commercialization of innovative medicines with a focus on immunology, oncology, and neuroscience
ISINUS00287Y1091
Market Capitalizationapprox. $497 billion
UMBRELLA StatusActive

UMBRELLA History

The key milestones of AbbVie within the UMBRELLA Strategy.

October 13, 2026
+
Entry

AbbVie Joins the UMBRELLA Strategy

Latest Developments

+
Entry
October 13, 2026

AbbVie Joins the UMBRELLA Strategy

AbbVie has been added to the UMBRELLA Strategy, strengthening its healthcare exposure with a focus on immunology and innovative therapies.

Price Performance (12 Months)

Aktuelle Unternehmensmeldungen

Alle Pressemeldungen Investor Relations

Latest Portfolio Updates

Strategy in Action

Alphabet – Position Further Increased

The UMBRELLA strategy further increases its Alphabet position. The focus is on the growth potential of artificial intelligence, Google Cloud,
Next Update
Weekly Update

Weekly Market Overview – October 5–October 11, 2026

Palantir becomes the largest UMBRELLA position. SpaceX gains, Dell is added, and Bayer exits. The focus on AI and technology
Next Update
MUMAK SpotLight

MUMAK Spotlight of the week: SpaceX takes the lead – Technology rotation continues

SpaceX becomes the largest position, Palantir gains weight, and Dell Technologies is newly added to the UMBRELLA Strategy.
Next Update
Weekly Update

Weekly Market Overview – September 28-October 4, 2026

The UMBRELLA Strategy increases its weighting in AI and semiconductors. Micron, Intel, Palantir, and SpaceX gain importance.
Next Update
All Portfolio Updates